Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.

Blakely, Collin M

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. [electronic resource] - Cancer discovery Oct 2012 - 872-5 p. digital

Publication Type: Journal Article

2159-8290

10.1158/2159-8290.CD-12-0387 doi


Cell Line, Tumor
Class I Phosphatidylinositol 3-Kinases
Drug Resistance, Neoplasm--genetics
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride
Gefitinib
Humans
Lung Neoplasms--drug therapy
Molecular Targeted Therapy
Mutation
Phosphatidylinositol 3-Kinases--genetics
Protein Kinase Inhibitors--pharmacology
Quinazolines--therapeutic use
Receptor, ErbB-2--biosynthesis